Literature DB >> 1355729

Somatostatin analogs in the treatment of acromegaly.

S W Lamberts1, J C Reubi, E P Krenning.   

Abstract

Medical therapy of acromegaly with the somatostatin analog octreotide is very successful. Both clinical symptomatology and hormonal hypersecretion by the growth hormone-secreting pituitary adenomas are controlled, and peripheral IGF-I levels also return to near normal levels. Tumor shrinkage is observed in most patients. Somatostatin analogs can be used after noncurative surgery and for a limited period after radiotherapy, and octreotide pretreatment might improve the outcome of surgery.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355729

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  4 in total

Review 1.  A risk-benefit assessment of octreotide in the treatment of acromegaly.

Authors:  A J van der Lely; W W de Herder; S W Lamberts
Journal:  Drug Saf       Date:  1997-11       Impact factor: 5.606

2.  Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.

Authors:  R Waśko; M Ruchała; J Sawicka; M Kotwicka; W Liebert; J Sowiński
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

3.  Effectiveness of long-acting octreotide in suppressing hormonogenesis and tumor growth in thyrotropin-secreting pituitary adenomas: report of two cases.

Authors:  L Gourgiotis; M C Skarulis; F Brucker-Davis; E H Oldfield; N J Sarlis
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

Review 4.  Pituitary tumors. Current concepts in diagnosis and management.

Authors:  D C Aron; J B Tyrrell; C B Wilson
Journal:  West J Med       Date:  1995-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.